Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > keep the enthusiasm in check
View:
Post by inthno on Mar 26, 2023 12:24pm

keep the enthusiasm in check

Yes we have had a great trial with the panc. But did anyone ever compare it to cornerstone pharmaceticals which had better results in their phase 1 trial than onc and then failed in their phase 3 trial. They actually had 3 cr's in their 20 patient orginal study, were allowed fast track but not AA....As Much as we all want this to work we need to understand that there is no guarantee and as much as I would like to see this partnered I would really prefer a buyout so as to not have to take a chance with the followup trial that might not prove out. I said before that 2 billion is reasonable considering all the risks that are still associated with future trials and really wonder if onc has ever been offered something similar and turned it down hoping for more. Just being a realist as the result and company comparisons so far are very similar.
Comment by Noteable on Mar 26, 2023 12:48pm
inthno - "NO" $2 Blillion is "not" reasonable given that ONCY has "de-risked" pelareorep beyond, for example, those companies that were acquired for  US$2-4 Billion who were only in the pre-clinical stage of development which I have listed as examples in multiple messages beforehand. For whatever reason, you seem to be conveniently forgetting those "risk-on ...more  
Comment by westcoast1000 on Mar 26, 2023 12:50pm
Good points inthno.
Comment by Noteable on Mar 26, 2023 12:52pm
Nonsense.
Comment by inthno on Mar 26, 2023 1:00pm
Not nonsense as the results of the cornerstone trials cannot be disputed. My main point is that if onc is in negotiations that would it not make sense to sell at a resonable price and remove all doubt for all of the shareholders especially the lifers than to take a CHANCE in the phase 3 while waitng 2-3 more years. You know the saying bird in the hand. As much as we think we are derisked there is ...more  
Comment by Noteable on Mar 26, 2023 1:21pm
Complete nonsense.  A "one-trial" is the quickest path to full approval and completely de-risks the product development process. And this acheivement comes with an absolute M&A premium. Furthermore ONCY's would be employing biomarker defined cohorts of patients which further de-risks the clinical trial
Comment by inthno on Mar 26, 2023 1:34pm
Yes the quickest path to full approval but not guaranteed no matter what you say. So you are suggesting to all of the people that follow you that if a 2 billion offer was put forward to shareholders , a guaranteed sale and money in their pocket that you would reccommend that we all turn the offer down. Nothing personal and as much as I do appreciate some of your posts, you are not nearly as savey ...more  
Comment by askretka on Mar 27, 2023 6:20am
That drug your referring to was combined with FOLFIRINOX in latest trial a much more toxic drug than what Pelareorep is combining with and requires a ECOG of 0 or 1. -------------------------------------- If you remember KOL the panel they said that they would have no problem putting patients of ECOG of 2 in the trial with pelareorep because of the excellent safety profile.  We're going ...more  
Comment by Lesalpes29 on Mar 27, 2023 10:39am
Keep posting here to have a balance point of vue. We have a product not good enough to be used alone. We are the little dog who needs a big dog with a proven product to have value. Less then 80 millions of market cap and almost no interest by buyers actually. Hope management will have a big NR to get the interest back. GL
Comment by westcoast1000 on Mar 27, 2023 4:10pm
Our virus may not be powerful ennough to kill enough cancer to be effective on its own. But it is very good in a LOT of indications and with a lot of other I/O agents by engaging the immune system. That more than makes up for the inability to work as a monotherapy. 
Comment by Capitalista on Mar 27, 2023 6:34pm
I agree, WC1000.  Combination therapies seem to be emerging as the way to go in immunotherapy - there is no "killer app" available yet in this research field.   The difference in overall response between combo therapies using Pela and those not (i.e. control arms) is what gives me hope.  I'm still waiting for ONC management to get Pela approved and monetize it. ...more  
Comment by Lesalpes29 on Mar 28, 2023 6:10am
Agree with both of you. Now what is the real value of a drug that could be used in many indications and in a mix of many? We will see I hope. GL
Comment by Buckhenry on Mar 27, 2023 8:10pm
we must be in a time warp here.... I swear I have heard all the same posts 3 years ago....  kickin the can do an the road....
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities